Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL184312 | 0.91 | PDE4B (1.00) | PDE4BPDE4D | |
| SCHEMBL184690 | 0.89 | PDE4B (0.81) | PDE4BPDE4D | |
| SCHEMBL184323 | 0.85 | PDE4B (1.00) | PDE4BPDE4D | |
| SCHEMBL183968 | 0.83 | PDE4B (1.00) | PDE4BPDE4D | |
| SCHEMBL2324578 | 0.83 | PDE4B (0.71) | PDE4BPDE4D | |
| SCHEMBL2325856 | 0.83 | PDE4B (0.71) | PDE4BPDE4D | |
| SCHEMBL196373 | 0.83 | PDE4B (1.00) | PDE4BPDE4D | |
| SCHEMBL184530 | 0.82 | PDE4B (1.00) | PDE4BPDE4D | |
| SCHEMBL2324312 | 0.82 | PDE4B (0.69) | PDE4BPDE4D | |
| Hydrochloric Acid SCHEMBL184546 | 0.81 | PDE4B (0.68) | PDE4BPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8304436-B2 | Pyrazolone derivatives as PDE4 inhibitors | NYCOMED GMBH (DE) | 2012-11-06 | — | — | US | claimed |
| EP-2148876-B1 | PYRAZOLONE DERIVATIVES AS PDE4 INHIBITORS | NYCOMED GMBH (DE) | 2011-09-28 | — | — | EP | claimed |
| US-20100120757-A1 | PYRAZOLONE DERIVATIVES AS PDE4 INHIBITORS | NYCOMED GMBH (DE) | 2010-05-13 | — | — | US | claimed |
| EP-2148876-A1 | PYRAZOLONE DERIVATIVES AS PDE4 INHIBITORS | Nycomed GmbH (DE) | 2010-02-03 | — | — | EP | claimed |
| WO-2008138939-A1 | PYRAZOLONE DERIVATIVES AS PDE4 INHIBITORS | NYCOMED GMBH (DE) | 2008-11-20 | — | — | WO | claimed |
| US-8865745-B2 | Pyrazolone derivatives as PDE4 inhibitors | TAKEDA GMBH (DE) | 2014-10-21 | — | — | US | disclosed |
| US-20130012544-A1 | PYRAZOLONE DERIVATIVES AS PDE4 INHIBITORS | NYCOMED GMBH (DE) | 2013-01-10 | — | — | US | disclosed |
| US-8304436-B2 | Pyrazolone derivatives as PDE4 inhibitors | NYCOMED GMBH (DE) | 2012-11-06 | — | — | US | disclosed |
| EP-2508520-A1 | Pyrazolone-derivatives as PDE4 inhibitors | Nycomed GmbH (DE) | 2012-10-10 | — | — | EP | disclosed |
| EP-2402330-A1 | Pyrazolone-derivatives as PDE4 inhibitors | Nycomed GmbH (DE) | 2012-01-04 | — | — | EP | disclosed |
| EP-2148876-B1 | PYRAZOLONE DERIVATIVES AS PDE4 INHIBITORS | NYCOMED GMBH (DE) | 2011-09-28 | — | — | EP | disclosed |
| US-20100120757-A1 | PYRAZOLONE DERIVATIVES AS PDE4 INHIBITORS | NYCOMED GMBH (DE) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120757-A1 | PYRAZOLONE DERIVATIVES AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE3A | PDE4B 2/4885PDE4D 8/4885 |
| US-20130012544-A1 | PYRAZOLONE DERIVATIVES AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE5A | PDE4B 2/4885PDE4D 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.